

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Concurrent Clade I and Clade II Monkeypox Virus Circulation, Cameroon, 1979–2022

Appendix

Appendix Table 1. Public monkeypox virus genomes used for phylogenetic analysis*

| No. | Country | Year | Original name | Name on tree | Host | Accession no. | Clade | Sub-clade | Lineage |
|-----|---------------|------|---------------------------------------|---------------------|----------|---------------|-------|-----------|---------|
| 1 | Cameroon | 1989 | Cameroon-1990 | Cameroon_1990 | Human | KJ642618 | I | I | 1 |
| 2 | Gabon | 1987 | Gabon 1988 | Gabon_1988 | Human | KJ642619 | I | I | 1 |
| 3 | Gabon | 1988 | BNITM-Gabon1988 | BNITM-Gabon_1988 | Human | OP498046 | I | I | 1 |
| 4 | DRC | 1970 | Congo_8 | Bokenda-Zaire_1970 | Human | KJ642613 | I | I | 2 |
| 5 | DRC | 2003 | Congo_2003_358 | Congo_2003_358 | Human | DQ011154 | I | I | 2 |
| 6 | CAR | 2018 | 015c_contig_SPADES | CAR_15c_2018 | Human | MN702448 | I | I | 2 |
| 7 | CAR | 2001 | A1_contig_SPADES | CAR_A1_2001 | Human | MN702453 | I | I | 2 |
| 8 | CAR | 2017 | A6_contig_SPADES | CAR_A6_2017 | Human | MN702451 | I | I | 2 |
| 9 | CAR | 2018 | A5_contig_SPADES | CAR_A5_2017 | Human | MN702444 | I | I | 2 |
| 10 | DRC | 1985 | Yambuku_DRC_1985 | Yambuku_DRC_1985 | Squirrel | KP849471 | I | I | 3 |
| 11 | DRC | 2006 | DRC_06–1074 | DRC_06–1075–2006 | Human | JX878411 | I | I | 3 |
| 12 | DRC | 2007 | DRC_07–0286 | DRC_07–0287–2007 | Human | JX878422 | I | I | 3 |
| 13 | DRC | 2007 | DRC_07–0283 | DRC_07–0283–2007 | Human | JX878420 | I | I | 3 |
| 14 | DRC | 1986 | Ikubi | Ikubi-Zaire_1986 | Human | KJ642612 | I | I | 4 |
| 15 | DRC | 1996 | Monkeypox virus | Zaire_1996 | Human | NC_003310 | I | I | 4 |
| 16 | DRC | 1979 | Zaire 1979–005 | Zaire_1979–005 | Human | HM172544 | I | I | |
| 17 | Gabon | 1998 | A-type inclusion body protein gene | Gabon-AT1gene_1998 | Human | U84504 | I | I | |
| 18 | DRC | 2007 | DRC_07–0104 | DRC_07–0104–2007 | Human | JX878417 | I | I | 5 |
| 19 | USA | 2022 | hMPXV/USA/CA-LACPHL-MA00154/2022 | USA_2022_MA00180 | Human | OP580587 | II | Ila | |
| 20 | USA | 1971 | Nigeria-SE-1970 | Nigeria_SE_1971 | Human | KJ642617 | II | Ila | |
| 21 | Nigeria | 2017 | MPXV_Nig_2017_298464 | Nigeria_2017_298464 | Human | MG693724 | II | Ila | |
| 22 | USA | 2022 | MPXV/Human/USA/CA-CDPH-MPX000040/2022 | USA_2022_MPX000040 | Human | OP587264 | II | Ila | |
| 23 | Liberia | 1970 | Liberia_1970_184 | Liberia_1970_185 | Human | DQ011156 | II | Ila | |
| 24 | Cote d'Ivoire | 1970 | Cote d'Ivoire_1971 | Ivory Coast_1971 | Human | KP849470 | II | Ila | |
| 25 | Sierra Leone | 1970 | Sierra Leone | Sierra Leone_1970 | Human | AY741551 | II | Ila | |
| 26 | USA | 1961 | MPXV-WRAIR7–61 | Walter Reed_1961 | Human | AY603973 | II | Ila | |
| 27 | USA | 2003 | USA_2003_039 | USA/Ghana_2003 | Human | DQ011157 | II | Ila | |
| 28 | France | 1968 | PCH | Paris_1968 | Human | KJ642616 | II | Ila | |
| 29 | Netherlands | 1965 | UTC | Rotterdam_1965 | Human | KJ642614 | II | Ila | |
| 30 | Denmark | 1958 | COP-58 | Copenhagen_1958 | Human | AY753185 | II | Ila | |
| 31 | Nigeria | 1978 | W-Nigeria | Nigeria_1978 | Human | KJ642615 | II | Ila | |
| 32 | Cote d'Ivoire | 2012 | Ivory Coast 2012 | Ivory Coast_2012 | Human | KJ136820 | II | Ila | |
| 33 | Germany | 2022 | MPXV/Germany/2022/RKI571 | Germany-RKI571_2022 | Human | OP764629 | II | Ila | |
| 34 | Germany | 2022 | MPXV/Germany/2022/RKI556 | Germany-RKI556_2022 | Human | OP764614 | II | Ila | |
| 35 | USA | 2022 | MPXV_USA_2022_OR0005 | USA_2022_OR0005 | Human | OP752116 | II | Ila | |
| 36 | Nigeria | 2017 | MPXV-M2957_Lagos | Nigeria_2017 | Human | MT903338.1 | II | Ilb | A |
| 37 | Nigeria | 2018 | MPXV-M3021_Delta | Nigeria_2018 | Human | MT903339.1 | II | Ilb | A |
| 38 | Singapore | 2019 | MPXV-Singapore | Singapore_2019 | Human | MT903342.1 | II | Ilb | A.1 |
| 39 | UK | 2018 | MPXV-UK_P2 | UK_2018 | Human | MT903344.1 | II | Ilb | A.1 |

| No. | Country | Year | Original name | Name on tree | Host | Accession no. | Clade | Sub-clade | Lineage |
|-----|-------------|------|----------------------------|--------------------|-------|---------------|-------|-----------|---------|
| 40 | Switzerland | 2022 | MPXV-CH-38134631/2022 | Switzerland_2022 | Human | ON595760.2 | II | IIB | B.1 |
| 41 | Italy | 2022 | INMI-Pt1 | Italy-2022 | Human | ON614676.1 | II | IIB | B.1 |
| 42 | Netherlands | 2022 | MPXV_2022_NL001 | Netherlands_2022 | Human | ON615424.1 | II | IIB | B.1 |
| 43 | UK | 2022 | MPXV_UK_2022_3 | UK_2022 | Human | ON619837.2 | II | IIB | B.1 |
| 44 | Belgium | 2022 | MPX/UZ_REGA_1/Belgium/2022 | Belgium_2022 | Human | ON622712.1 | II | IIB | B.1 |
| 45 | France | 2022 | MPXV_FR_HCL0001_2022 | France_2022 | Human | ON622722.2 | II | IIB | B.1 |
| 46 | Australia | 2022 | MPxV/VIDRL01/2022 | Australia_2022 | Human | ON631963.1 | II | IIB | B.1 |
| 47 | Portugal | 2022 | Monkeypox/PT0027/2022 | Portugal_2022 | Human | ON649710.1 | II | IIB | B.1 |
| 48 | USA | 2022 | MPXV_USA_2022_FL001 | USA_2022_FL001 | Human | ON674051.1 | II | IIB | A.2 |
| 49 | USA | 2022 | MPXV_USA_2022_VA001 | USA_2022_VA001 | Human | ON675438.1 | II | IIB | A.2 |
| 50 | USA | 2022 | MPXV_USA_2022_UT002 | USA_2022_UT002 | Human | ON676706.1 | II | IIB | B.1 |
| 51 | USA | 2021 | MPXV_USA_2021_TX | USA_2021_TX | Human | ON676707.1 | II | IIB | A.2 |
| 52 | USA | 2021 | MPXV_USA_2021_MD | USA_2021_MD | Human | ON676708.1 | II | IIB | A.1.1 |
| 53 | Germany | 2022 | MPXV/Germany/2022/RK105 | Germany_2022_RK105 | Human | ON682264.4 | II | IIB | B.1 |
| 54 | Canada | 2022 | MPX/2022/Canada/AB1 | Canada_2022 | Human | ON736420.1 | II | IIB | B.1 |
| 55 | Israel | 2018 | Israel_2018 | Israel_2018 | Human | MN648051.1 | II | IIB | A.1 |

*Available in GenBank (<https://www.ncbi.nlm.nih.gov/genbank>). CAR, Central African Republic; DRC, Democratic Republic of the Congo; UK, United Kingdom; USA, United States of America.

Appendix Table 2. Epidemiologic and molecular features of monkeypox virus sequences obtained from Cameroon

| No. | Country | Age, y/sex | Collection year | Original SEQ_ID | SEQ_ID on tree | Host | Isolation source region/health district | MPXV clade | Accession no. |
|-----|----------|------------|-----------------|-----------------|----------------|-------|---|------------|---------------|
| 1 | Cameroon | 36/F | 2022 | 22V-0972 | 22V-0972 | Human | South-West/Benakuma | II | OR038717 |
| 2 | Cameroon | 10/M | 2022 | 22V-06957 | 22V-06957 | Human | South/Djoum | I | OR038718 |
| 3 | Cameroon | 6/F | 2022 | 22V-04639 | 22V-04639 | Human | Centre/Ayos | I | OR038719 |
| 4 | Cameroon | 20/M | 2022 | 22V-04865 | 22V-04865 | Human | Centre/Ayos | I | OR038720 |
| 5 | Cameroon | 11/F | 2022 | 22V-07739 | 22V-07739 | Human | South-West/Kumba South | II | OR038721 |
| 6 | Cameroon | 52/M | 2022 | 22V-07911 | 22V-07911 | Human | South-West/Deido-Tombel | II | OR038722 |
| 7 | Cameroon | 40/M | 2022 | 22V-05210 | 22V-05210 | Human | Centre/Ayos | I | OR038723 |
| 8 | Cameroon | 43/M | 2022 | 22V-07968 | 22V-07968 | Human | South-West/Tombel | II | OR038724 |

Appendix Table 3. Epidemiologic information of mpox confirmed cases in Cameroon, 1979–2022

| No. | CPC code | Country | Region | Age, y/sex | Patient progress | MPXV PCR | MPXV clade | VZV PCR | Date | |
|-----|-----------|----------|-----------|------------|------------------|----------|------------|---------|---------------|-------------|
| | | | | | | | | | Disease onset | Sampling |
| 1 | UNK | Cameroon | Centre | 4/F | Unk | + | UNK | UNK | UNK | 1979 Jan 1 |
| 2 | UNK | Cameroon | East | 3/M | Unk | + | UNK | UNK | UNK | 1980 Jan 1 |
| 3 | UNK | Cameroon | Centre | 7/M | Alive | + | I | UNK | 1989 Dec 4 | 1989 Dec 11 |
| 4 | 18V-04552 | Cameroon | Northwest | 20/M | Alive | + | II | UNK | UNK | 2018 May 4 |
| 5 | 19V-06906 | Cameroon | Southwest | 14/M | Alive | + | II | UNK | 2019 Sep 7 | 2019 Sep 19 |
| 6 | 20V-00071 | Cameroon | Centre | 27/F | Alive | + | I | – | 2020 Jan 3 | 2020 Jan 4 |
| 7 | 20V-02998 | Cameroon | East | 36/M | Alive | + | I | – | 2020 Mar 14 | 2020 Mar 24 |
| 8 | 20V-14349 | Cameroon | East | 31/F | Alive | + | I | – | 2020 Aug 26 | 2020 Sep 6 |
| 9 | 20V-14644 | Cameroon | Centre | 46/M | Alive | + | I | – | 2020 Sep 16 | 2020 Sep 23 |
| 10 | 20V-14645 | Cameroon | Centre | 43/F | Alive | + | I | – | 2020 Sep 18 | 2020 Sep 23 |
| 11 | 21V-04877 | Cameroon | Centre | 30/F | Alive | + | II | UNK | UNK | 2021 Jul 22 |
| 12 | 21V-09233 | Cameroon | Centre | 11/M | Alive | + | I | – | 2021 Dec 3 | 2021 Dec 13 |
| 13 | 21V-09234 | Cameroon | Centre | 8/M | Alive | + | I | – | 2021 Nov 27 | 2021 Dec 15 |

| No. | CPC code | Country | Region | Age, y/sex | Patient progress | MPXV PCR | MPXV clade | VZV PCR | Date | |
|-----|-----------|----------|-----------|------------|------------------|----------|------------|---------|---------------|-------------|
| | | | | | | | | | Disease onset | Sampling |
| 14 | 21V-09565 | Cameroon | Southwest | 0/M | Alive | + | II | - | 2021 Dec 22 | 2021 Dec 29 |
| 15 | 21V-09567 | Cameroon | Southwest | 31/M | Dead | + | II | - | 2021 Dec 23 | 2021 Dec 29 |
| 16 | 22V-00302 | Cameroon | Southwest | 27/F | Alive | + | II | - | 2021 Dec 27 | 2022 Jan 27 |
| 17 | 22V-00972 | Cameroon | Northwest | 36/F | Alive | + | II | - | UNK | 2022 Feb 16 |
| 18 | 22V-00973 | Cameroon | Northwest | 1/F | Alive | + | II | - | UNK | 2022 Feb 16 |
| 19 | 22V-04639 | Cameroon | Centre | 10/M | Alive | + | I | - | 2022 Jun 9 | 2022 Jun 13 |
| 20 | 22V-04865 | Cameroon | Centre | 6/F | Alive | + | I | - | 2022 Jun 20 | 2022 Jun 21 |
| 21 | 22V-05210 | Cameroon | Centre | 20/M | Alive | + | I | - | 2022 Jun 28 | 2022 Jul 4 |
| 22 | 22V-06957 | Cameroon | South | 11/F | Alive | + | I | - | 2022 Sep 5 | 2022 Sep 7 |
| 23 | 22V-07739 | Cameroon | Southwest | 52/M | Alive | + | II | - | 2022 Sep 19 | 2022 Oct 6 |
| 24 | 22V-07911 | Cameroon | Littoral | 40/M | Alive | + | II | - | 2022 Sep 25 | 2022 Oct 11 |
| 25 | 22V-07968 | Cameroon | Southwest | 43/M | Alive | + | II | - | UNK | 2022 Oct 13 |
| 26 | 22V-08077 | Cameroon | Southwest | 23/F | Alive | + | II | - | 2022 Oct 12 | 2022 Oct 14 |
| 27 | 22V-08300 | Cameroon | Northwest | 28/M | Alive | + | II | - | 2022 Oct 14 | 2022 Oct 22 |
| 28 | 22V-08501 | Cameroon | Southwest | 23/M | Alive | + | II | - | UNK | 2022 Oct 27 |
| 29 | 22V-08502 | Cameroon | Southwest | 18/M | Alive | + | II | - | UNK | 2022 Oct 27 |
| 30 | 22V-08503 | Cameroon | Southwest | 0/M | Alive | + | II | - | UNK | 2022 Oct 26 |
| 31 | 22V-09327 | Cameroon | Northwest | 1/M | Alive | + | II | - | 2022 Nov 3 | 2022 Nov 8 |
| 32 | 22V-09403 | Cameroon | Northwest | 43/M | Alive | + | II | - | 2022 Nov 2 | 2022 Nov 11 |

*CPC, Centre Pasteur du Cameroun; MPXV, monkeypox virus; UNK, unknown; VZV, +, positive; -, negative

Appendix Table 4. Severity of monkeypox virus clades in 30 confirmed cases in Cameroon from 1979 to 2022

| Clinical Characteristics | MPXV RT-PCR, no. (%) | | Crude OR (95% CI) | p value |
|------------------------------|-------------------------|--------------------------|---------------------|---------|
| | Clade I, n = 12 (40.00) | Clade II, n = 18 (60.00) | | |
| Active Skin Lesions | | | | |
| Y | 12 (100.00) | 17 (94.44) | 1 (Referent) | 0.995 |
| N | 0 (0.00) | 1 (5.56) | 0 (0.00–58.5) | |
| Missing | 0 | 0 | NA | |
| Lesion progress | | | | |
| Diffuse | 1 (14.29) | 4 (33.33) | 1 (Referent) | 0.066 |
| Head to limbs | 0 (00.00) | 4 (33.33) | 0.00 (0 to ∞) | |
| Limbs to head | 3 (42.86) | 3 (25.00) | 4.00 (0.27–60.32) | |
| Others | 3 (42.86) | 1 (8.33) | 12.00 (0.51–280.09) | |
| Missing | 5 | 6 | NA | |
| Lesions at same stage | | | | |
| Y | 7 (70.00) | 6 (46.15) | 1 (Referent) | 0.249 |
| N | 3 (30.00) | 7 (53.85) | 2.72 (0.48–15.47) | |
| Missing | 2 | 5 | NA | |
| Lesions of same size | | | | |
| Y | 8 (80.00) | 5 (38.46) | 1 (Referent) | 0.057 |
| N | 2 (20.00) | 8 (61.54) | 6.4 (0.95–43.23) | |
| Missing | 2 | 5 | NA | |
| Lesions deep | | | | |
| Y | 4 (40.00) | 7 (53.85) | 1 (Referent) | 0.511 |
| N | 6 (60.00) | 6 (46.15) | 0.57 (0.11–3.04) | |
| Missing | 2 | 5 | NA | |
| Fever before rash | | | | |
| Y | 12 (100.00) | 10 (71.43) | 1 (Referent) | 0.995 |
| N | 0 (0.00) | 4 (28.57) | 0.00 (0.00–1.61) | |
| Missing | 0 | 4 | NA | |
| Headache | | | | |
| Y | 9 (75.00) | 6 (53.85) | 1 (Referent) | 0.149 |
| N | 3 (25.00) | 7 (46.15) | 3.50 (0.64–19.19) | |
| Missing | 0 | 5 | NA | |
| Cough | | | | |
| Y | 7 (58.33) | 6 (40.00) | 1 (Referent) | 0.346 |
| N | 5 (41.67) | 9 (60.00) | 2.1 (0.45–9.84) | |

| Clinical Characteristics | MPXV RT-PCR, no. (%) | | Crude OR (95% CI) | p value |
|--------------------------------------|-------------------------|--------------------------|-------------------|--------------|
| | Clade I, n = 12 (40.00) | Clade II, n = 18 (60.00) | | |
| Missing | 0 | 3 | NA | |
| Vomiting, nausea | | | | |
| Y | 2 (16.67) | 2 (14.29) | 1 (Referent) | 0.867 |
| N | 10 (83.33) | 12 (85.71) | 1.20 (0.14–10.12) | |
| Missing | 0 | 4 | NA | |
| Chills, sweat | | | | |
| Y | 8 (66.67) | 10 (66.67) | 1 (Referent) | 1.000 |
| N | 4 (33.33) | 5 (33.33) | 1.00 (0.20–5.00) | |
| Missing | 0 | 3 | NA | |
| Lymphadenopathy | | | | |
| Y | 8 (66.67) | 10 (71.43) | 1 (Referent) | 0.059 |
| N | 4 (33.33) | 4 (28.57) | 5.00 (0.94–26.53) | |
| Missing | 0 | 4 | NA | |
| Sore throat when swallowing | | | | |
| Y | 9 (75.00) | 7 (50.00) | 1 (Referent) | 0.199 |
| N | 3 (25.00) | 7 (50.00) | 3.00 (0.56–16.01) | |
| Missing | 0 | 4 | NA | |
| Oral ulcer | | | | |
| Y | 8 (66.67) | 3 (21.43) | 1 (Referent) | 0.026 |
| N | 4 (33.33) | 11 (78.57) | 7.33 (1.27–42.29) | |
| Missing | 0 | 4 | NA | |
| Itchy lesions | | | | |
| Y | 11 (91.67) | 8 (53.33) | 1 (Referent) | 0.052 |
| N | 1 (8.33) | 7 (46.67) | 9.62 (0.98–94.54) | |
| Missing | 0 | 3 | NA | |
| General fatigue | | | | |
| Y | 10 (83.33) | 10 (66.67) | 1 (Referent) | 0.334 |
| N | 2 (16.67) | 5 (33.33) | 2.5 (0.39–16.05) | |
| Missing | 0 | 3 | NA | |
| Myalgia | | | | |
| Y | 5 (41.67) | 4 (28.57) | 1 (Referent) | 0.486 |
| N | 7 (58.33) | 10 (71.43) | 1.79 (0.35–9.13) | |
| Missing | 0 | 4 | NA | |
| Conjunctivitis | | | | |
| Y | 1 (8.33) | 1 (7.14) | 1 (Referent) | 0.910 |
| N | 11 (91.67) | 13 (92.86) | 1.18 (0.07–21.17) | |
| Missing | 0 | 4 | NA | |
| Contact with human case | | | | |
| Y | 7 (58.33) | 10 (62.50) | 1 (Referent) | 0.510 |
| N | 5 (41.67) | 5 (31.25) | 1.42 (0.30–6.88) | |
| Unknown | 0 (0.00) | 1 (6.25) | 0.00 (0 to ∞) | |
| Missing | 0 | 2 | NA | |
| Contact with animal | | | | |
| Y | 7 (58.33) | 5 (38.46) | 1 (Referent) | 0.570 |
| N | 4 (33.33) | 7 (53.85) | 0.40 (0.08–2.19) | |
| Unknown | 1 (8.33) | 1 (7.69) | 0.71 (0.04–14.35) | |
| Missing | 0 | 5 | NA | |
| Contact with wild or domestic animal | | | | |
| Domestic animal | 2 (20.00) | 1 (10.00) | 1 (Referent) | 0.397 |
| Wild animal | 4 (40.00) | 2 (20.00) | 1.00 (0.05–18.91) | |
| No contact | 4 (40.00) | 7 (70.00) | 0.29 (0.02–4.24) | |
| Missing | 2 | 8 | NA | |

*Bold text indicates statistical significance. MPXV, monkeypox virus; NA, not applicable; OR, odds ratio; RT-PCR, reverse transcription PCR.